RISPERIDONE DEPOT vs OLANZAPINE: Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months)
- Population
- patients with schizophrenia
- Intervention
- RISPERIDONE DEPOT
- Comparison
- OLANZAPINE
- Outcome
- Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months)
RISPERIDONE DEPOT may leads to higher adverse events: Movement disorder ‐ any extra pyramidal symptoms compared with ORAL OLANZAPINE (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
RISPERIDONE DEPOT vs ORAL OLANZAPINE Adverse events: Movement disorder ‐ any extra pyramidal symptoms · patients with schizophrenia RISPERIDONE DEPOT may leads to higher adverse events: Movement disorder ‐ any extra pyramidal symptoms compared with ORAL OLANZAPINE (low certainty). Risperidone (depot) for schizophrenia (2016) · Cochrane Headline outcomes only | RR 1.67 [1.19, 2.36] | 1 study · 547 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- RISPERIDONE DEPOT vs ARIPIPRAZOLE · patients with schizophrenia · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.